Looking for:
Betamethasone inhaler dose |
Betamethasone inhaler dose. Beclometasone
This information is not country-specific. Please refer to the Malaysia prescribing information. Indications and Dosage. All doses are given in 2 divided doses. Usual maintenance dose: mcg daily in 2 divided doses, titrated to the lowest effective dose.
Max: mcg up to 2 mg may be necessary in severe cases daily in divided doses. Max: mcg daily. Adult: As spray: mcg into each nostril bid, or 50 mcg in each nostril times daily.
Adult: As modified-release tab: 5 mg once daily in the morning, before or after breakfast, for mild to moderate cases. Max duration: 4 wk. Adult: 0. As primary treatment of status asthmaticus or acute episodes of asthma requiring intensive measures inhalation. Special Precautions. Renal and hepatic e. Pregnancy and lactation. Adverse Reactions. Patient Counseling Information. Monitoring Parameters. Monitor growth annually during long term use in childn.
Assess for ocular changes, signs and symptoms of adrenal insufficiency, and oral candidiasis. It controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes, reduces fibroblast activity, and reverses capillary permeability and lysosomal stabilisation at the cellular level to prevent or control inflammation.
Pharmacokinetics: Absorption: Readily absorbed from the resp and GI tract. Time to peak plasma concentration: 0. Distribution: Rapidly distributed to all body tissues. Volume of distribution: 20 L. Metabolism: Undergoes hydrolysis by pulmonary esterases to major active metabolite, beclometasonemonopropionate BMPduring absorption; subsequently undergoes metabolism in the liver by CYP3A4 enzyme to less active metabolites, beclometasonemonopropionate BMP and beclometasone.
Elimination half-life: 0. Chemical Structure. PubChem Database. Protect from heat or open flame. MIMS Class. ATC Classification. R03BA01 - beclometasone ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids. R01AD01 - beclometasone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis.
Used in the treatment of dermatological diseases. A07EA07 - beclometasone ; Belongs to the class of corticosteroids acting locally.
Used in the treatment of intestinal inflammation. Beclomethasone Nasal. Lexicomp Online. Hudson, Ohio. Beclomethasone Oral Inhalation. Elsevier Inc. Buckingham R ed. Beclometasone Dipropionate. Martindale: The Complete Drug Reference [online]. Pharmaceutical Press. Interactions of Corticosteroids.
Joint Formulary Committee. British National Formulary [online]. Beclomethasone Dipropionate. Mylan New Zealand Limited. Alanase Aqueous Nasal Spray data sheet 16 June Source: U. National Library of Medicine. Disclaimer: This information is independently developed by MIMS based on Beclometasone from various references and is provided for your reference only.
Therapeutic uses, prescribing information and product availability may vary between countries. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise.
All rights reserved. Powered by MIMS. Available Brands. Other Known Brands. Related Diseases. Register or sign in to continue. Continue with Google. Sign Up. Already a member? Sign in. Nasal Treatment and prophylaxis of allergic and non-allergic rhinitis Adult: As spray: mcg into each nostril bid, or 50 mcg in each nostril times daily.
Oral Ulcerative colitis Adult: As modified-release tab: 5 mg once daily in the morning, before or after breakfast, for mild to moderate cases. Contraindications As primary treatment of status asthmaticus or acute episodes of asthma requiring intensive measures inhalation. Patient Counseling Information Rinse mouth thoroughly after inhalation. Monitoring Parameters Monitor growth annually during long term use in childn. ATC Classification R03BA01 - beclometasone ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.
References Anon.
- Beclometasone: Indication, Dosage, Side Effect, Precaution | MIMS Malaysia
Betamethasone inhaler dose.PDR Search
As well as beclometasone inhalers, there are other "preventers" that contain steroids such as budesonide, ciclesonide and fluticasone.
They can look very different, and some are for adults only. It's important to use your own beclometasone inhaler. Your inhaler may be different to a friend's or relative's. Their inhaler might contain a different dose of beclometasone. Preventer inhalers are different from the inhalers used during asthma attacks.
These are called bronchodilators or "reliever" inhalers. Bronchodilators also known as "relievers" work by relaxing the muscles of the airways into the lungs.
This makes it easier to breathe. A Fostair inhaler can be used as both a preventer and a reliever to relieve any symptoms when you get them. This means you may use it more often. Your GP may tell you to use it every day as a preventer and also during an asthma attack as a reliever.
Always follow the instructions from your doctor. If you are prescribed steroid medicines such as beclometasone, your adrenal glands may not make as much of some of the hormones your body needs such as cortisol known as the stress hormone. This is known as adrenal insufficiency. This card is the size of a credit card and fits in your wallet or purse.
If you need any medical or dental treatment, or are having surgery or an invasive procedure, show your steroid emergency card to your doctor or dentist. This is important so they know you are having steroid treatment and can give you extra steroids as needed.
If you are on a high dose of beclometasone, your doctor or pharmacist will also give you a blue steroid treatment card. It tells you how you can reduce the risks of side effects. It also gives details of your doctor, how much beclometasone you take and how long the treatment will last for.
If you need any medical or dental treatment, show your blue steroid card to the doctor or dentist. There's no clear evidence to suggest that taking beclometasone will reduce fertility in either men or women. However, speak to a pharmacist or your doctor if you are trying to get pregnant.
Beclometasone does not affect any type of contraception including the contraceptive pill and emergency contraception. Try not to smoke. Smoking irritates the lungs and will make your breathing problem worse.
Speak to your doctor, nurse or pharmacist if you're finding it hard to stop smoking. Stop smoking treatments are available on the NHS. For most people, using a beclometasone inhaler will not affect their ability to drive a car or cycle. There are several things you can do to help your condition when you're living with asthma. These include:. Some people say that using an air filter or air purifier helps with their asthma symptoms. However, there needs to be more research into this.
Page last reviewed: 18 March Next review due: 18 March Beclometasone inhalers - Brand names: Clenil, Qvar On this page About inhaled beclometasone Key facts Who can and cannot use beclometasone inhalers How and when to use your inhaler Side effects How to cope with side effects Pregnancy and breastfeeding Cautions with other medicines Common questions.
About inhaled beclometasone Beclometasone inhalers sometimes called "puffers" are used for asthma and chronic obstructive pulmonary disease COPD. It also comes as: nose spray nasal spray — for hay fever and cold-like symptoms caused by common allergies rhinitis cream and ointment — for skin conditions such as eczema and psoriasis tablets — for ulcerative colitis.
Use your beclometasone inhaler every day for it to work, even if you do not have any symptoms. It's important to rinse your mouth or brush your teeth after using a steroid preventer inhaler. This is to prevent infections and a sore mouth. You may get a blue steroid treatment card if you need high doses of beclometasone to control your symptoms.
You may also need to carry a steroid emergency card. Ask your pharmacist or doctor about both of these. Beclometasone sometimes comes mixed with formoterol. This type of inhaler is both a preventer and a reliever, and brand names include Fostair. Do not change your brand of steroid inhaler without checking with your doctor first. Adults can use beclometasone inhalers for asthma or COPD. To make sure it's safe for you, tell your doctor if you: have had an allergic reaction to beclometasone or any other medicines in the past cannot have alcohol for any reason some brands contain a very small amount of alcohol have ever had TB tuberculosis are pregnant or trying to get pregnant — your doctor may want to lower your dose are being treated for viral or fungal infections.
The usual dose is 1 or 2 puffs, taken twice a day. Different types of inhalers There are different types of beclometasone inhaler.
Information: Watch a video Asthma UK has some short videos showing you how to use your inhaler to help you manage your symptoms. Check your inhaler technique To get the most from your inhaler, it's important to have your technique checked regularly. Using your inhaler with a spacer If you or your child find it difficult to use an inhaler, your doctor or nurse may give you a spacer to use with it.
Will my dose go up or down? What if I forget to use it? Do not take a double dose to make up for a forgotten dose. What if I take too much? Taking too much beclometasone by accident is unlikely to harm you. If you're worried, talk to your doctor or a pharmacist. Steroid cards If you are using a steroid inhaler regularly, ask your doctor, nurse or a pharmacist if you need to carry a blue steroid card. Important: Important If you need any medical or dental treatment, show your blue steroid card to the doctor, dentist or pharmacist so they know that you're taking beclometasone.
Common side effects These common side effects may happen in more than 1 in people. Keep taking the medicine but talk to your doctor if these side effects bother you or do not go away: oral thrush — a fungal infection that causes white patches, redness and soreness in your mouth dry or sore throat, or hoarse voice Serious side effects It's unusual to have any serious side effects when using a beclometasone inhaler.
Tell a doctor straight away if you get: high temperature, chills, a very sore throat, ear or sinus pain, a cough, coughing up more mucus phlegm or a change in colour of your mucus, pain when you pee, mouth sores or a wound that will not heal — these can be signs of an infection "moon face" a puffy, rounded face , weight gain in the upper back or belly — this happens gradually and can be a sign of Cushing's syndrome a very upset stomach or you're being sick vomiting , very bad dizziness or passing out, muscle weakness, very tired, mood changes, loss of appetite and weight loss — these can be signs of adrenal gland problems changes in your eyesight, such as blurred vision or a cloudy lens in the eye — these can be signs of increased pressure in your eyes glaucoma or a cataract Serious allergic reaction It happens rarely but it is possible to have a serious allergic reaction anaphylaxis to beclometasone.
Children and teenagers Taking beclometasone at higher doses for a long time can slow down the normal growth of children and teenagers. Information: You can report any suspected side effect to the UK safety scheme. What to do about: oral thrush — try rinsing your mouth with water or brushing your teeth after using your inhaler to stop this happening. If you get oral thrush ask a pharmacist to recommend a suitable treatment such as a mouth gel and get them to check that you're using your inhaler correctly.
They may suggest that you see your doctor to discuss the best treatment. Using a spacer with your inhaler can also help. Assess for ocular changes, signs and symptoms of adrenal insufficiency, and oral candidiasis. It controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes, reduces fibroblast activity, and reverses capillary permeability and lysosomal stabilisation at the cellular level to prevent or control inflammation.
Pharmacokinetics: Absorption: Readily absorbed from the resp and GI tract. Time to peak plasma concentration: 0. Distribution: Rapidly distributed to all body tissues. Volume of distribution: 20 L. Metabolism: Undergoes hydrolysis by pulmonary esterases to major active metabolite, beclometasonemonopropionate BMP , during absorption; subsequently undergoes metabolism in the liver by CYP3A4 enzyme to less active metabolites, beclometasonemonopropionate BMP and beclometasone.
Elimination half-life: 0. Chemical Structure. PubChem Database. Protect from heat or open flame. MIMS Class. ATC Classification. R03BA01 - beclometasone ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids. R01AD01 - beclometasone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis.
Used in the treatment of dermatological diseases. A07EA07 - beclometasone ; Belongs to the class of corticosteroids acting locally. Used in the treatment of intestinal inflammation. Beclomethasone Nasal. Lexicomp Online. Hudson, Ohio. Beclomethasone Oral Inhalation. Elsevier Inc. Buckingham R ed. After administration, have patient rinse mouth thoroughly with water without swallowing to remove beclomethasone deposited in the mouth.
Keep the inhaler clean and dry. For normal hygiene, clean the mouthpiece of the inhaler with a clean dry tissue or cloth. Do not put any part of the Redihaler in water; if washed or placed in water the inhaler must be replaced. Never take the Redihaler apart. Throw away the Redihaler when the dose counter displays 0 background will be a solid red or the product expires, whichever comes first. Do not throw away in a fire or incinerator.
Storage: Keep the white cap on the inhaler closed during storage. Store so the inhaler rests on the concave end of the canister with the plastic actuator on top when not being used. Store at room temperature. Do not use or store near heat or open flame.
Exposure to temperatures above degrees F 49 degrees C may cause the canister to burst. Different nasal dosage forms are commercially available. Products are not always interchangeable due to differences in route of administration and in the amount of active drug released per spray. To avoid the spread of infection, do not use the container for more than 1 person.
Nasal inhalation metered-dose aerosol i. Prior to first use, instruct the patient to prime the pump by actuating 4 times into the air, away from the eyes and face. After the initial priming, the dose-counter should read actuation products or 60 actuation products. If the canister is not used for 7 consecutive days, instruct the patient to prime by actuating 2 times. Instruct patient on proper administration technique see manufacturer-provided patient instructions.
After administration, wipe the nasal actuator tip with a clean, dry tissue or cloth. Replace the cap right after cleaning. Nasal inhalation pump spray e. Prior to first use, instruct the patient to prime the pump by actuating 6 times into the air or until a fine spray appears, away from the eyes and face. If the pump is not used for 7 consecutive days, instruct the patient to prime by actuating until a fine spray appears.
After administration, rinse the tip of the bottle with hot water, taking care not to suck water into the bottle, and dry with a clean tissue. Beconase AQ: - Store at room temperature between 59 to 86 degrees F Qnasl: - Exposure to temperatures above degrees F may cause bursting - Keep away from heat and flame - Protect from freezing - Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F - Store upright Qnasl Children's: - Exposure to temperatures above degrees F may cause bursting - Keep away from heat and flame - Protect from freezing - Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F - Store upright QVAR: - Exposure to temperatures above degrees F may cause bursting - Flammable, keep away from heat and flame - Store at 77 degrees F; excursions permitted to degrees F QVAR RediHaler: - Exposure to temperatures above degrees F may cause bursting - Flammable, keep away from heat and flame - Store at 77 degrees F; excursions permitted to degrees F.
Use of beclomethasone does not contraindicate administration of live-virus vaccines. According to the Advisory Committee on Immunization Practices ACIP , administration of live-virus vaccines is safe and effective when steroid therapy is administered by the inhalation route. Inhaled beclomethasone is contraindicated as primary therapy for patients with status asthmaticus or other types of acute episodes of asthma, such as acute bronchospasm, for which intensive and immediate therapy is warranted.
Patients should be advised that beclomethasone is not to be used as a bronchodilator and is not indicated for relief of acute bronchospasm.
Although inhaled corticosteroids ICSs are not indicated for primary treatment of an acute exacerbation, they may be initiated at any time during an exacerbation for patients not using long-term control therapy. An ICS may also be continued during an exacerbation for patients previously using the drug for chronic control. Additionally, the drug is contraindicated for use in any patient with a known hypersensitivity to beclomethasone. As with other inhaled asthma medications, paradoxical bronchospasm can occur with an immediate increase in wheezing after administration of inhaled beclomethasone that may be life-threatening.
If bronchospasm occurs after dosing, treat the patient immediately with a fast-acting inhaled bronchodilator, discontinue beclomethasone, and institute alternative therapy. Systemic absorption of inhaled or intranasal beclomethasone may result in varying complications depending on the clinical situation and type of administration.
Carefully observe patients for evidence of systemic corticosteroid effects and adrenal insufficiency, particularly during periods of physiologic stress e. Systemic absorption of inhaled or intranasal corticosteroids has produced reversible hypothalamic-pituitary-adrenal HPA suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients; use with caution in patient's with underlying Cushing's syndrome.
To minimize the risk of HPA dysfunction, do not exceed recommended dosages and titrate patients to the lowest effective dosage. Patients with low body mass index BMI may have an increased risk of HPA suppression; some experts recommend adrenal screening in this population. If signs of HPA suppression occur, the drug should be slowly reduced; intranasal corticosteroids should be ultimately discontinued. If HPA suppression occurs with any beclomethasone formulation, patients will require systemic corticosteroids during periods of physiologic stress.
If surgery is required, patients should notify all health care providers that they have received corticosteroids within the last 12 months. Use beclomethasone with caution when substituting it for systemic corticosteroid administration and avoid abrupt discontinuation; deaths due to adrenal insufficiency have been reported in asthma patients during and after such a change. Beclomethasone may not produce systemic concentrations high enough to avoid adrenocortical insufficiency in patients transitioning from systemic corticosteroids.
Adult patients who have been maintained on at least 20 mg of prednisone equivalent may be most susceptible; the precise dosage that increases risk in children is not as clearly defined.
Recommended doses of inhaled corticosteroids ICSs provide less than normal physiologic amounts of systemic glucocorticoid and do not provide the mineralocorticoid necessary for coping with stress. Patients receiving ICS may require initiation or resumption of systemic corticosteroids during periods of stress or during severe asthma attacks. When transferring patients to ICS therapy, systemic corticosteroids should be weaned slowly. Monitor patients closely for asthma control e.
Infrequently, signs and symptoms of corticosteroid withdrawal may occur, requiring supplemental systemic corticosteroids. The incidence or course of acute viral infection or bacterial infection is probably minimally affected by inhaled corticosteroids in most immunocompetent individuals.
However, the use of inhaled beclomethasone in the presence of infection, specifically active or latent tuberculosis of the respiratory tract; untreated systemic fungal, bacterial, parasitic, or viral infections; or ocular herpes infection should be initiated or continued cautiously, if at all.
Because of the potential for worsening infection, beclomethasone therapy may need to be interrupted during some active infections. Chickenpox varicella and measles can have a more serious or even fatal course in susceptible children using corticosteroids; the exact risk associated with inhaled beclomethasone is unclear.
If an unimmunized patient is exposed to chickenpox or measles, proper prophylaxis may be indicated. Corticosteroid therapy can reactivate tuberculosis and should not be used except when chemoprophylaxis is instituted concomitantly.
The use of nasal or orally inhaled beclomethasone may result in localized fungal infection of the nose, mouth, and pharynx with Candida albicans. Instruct patients to rinse mouth after each use of orally inhaled beclomethasone to minimize risk.
If oropharyngeal candidiasis develops, it should be treated with appropriate local or systemic antifungal therapy while still continuing beclomethasone therapy; temporary interruption of inhaler use should only be done under close medical supervision. Patients using beclomethasone nasal spray for extended periods i.
Detrimental effects on bone metabolism, such as osteoporosis, are expected to be much lower with inhaled corticosteroids than systemically-administered corticosteroids.
Compounding risk factors for bone loss include preexisting osteopenia, prolonged immobilization, family history of osteoporosis, tobacco smoking, malnutrition, and use of other medications that may reduce bone mass. Nasal septal perforation and ulceration have been reported with intranasal beclomethasone use.
As with any long-term topical treatment of the nasal cavity, patients using intranasal beclomethasone over several months or longer should be examined periodically for possible changes in the nasal mucosa. Furthermore, because of the inhibitory effect of corticosteroids on wound healing, patients who have experienced recent nasal septal perforation or ulcer, nasal surgery, or nasal trauma should not use a nasal corticosteroid until healing has occurred.
There are no adequate and well-controlled studies with beclomethasone in pregnant women; there are clinical considerations with the use of beclomethasone in pregnant women. Current studies of beclomethasone therapy during pregnancy are incomplete; but published medical literature describing the drug's use during gestation does exist. Despite adverse effects observed with the parenteral use of beclomethasone in animal studies, fetal harm from inhaled administration in humans appears remote.
Human reports evaluating the use of inhaled beclomethasone currently do not support an association between drug use and congenital defects.
Infants and neonates born of mothers receiving substantial doses of beclomethasone during pregnancy should, however, be observed for adrenal suppression. A position statement by the American College of Allergy, Asthma and Immunology notes that beclomethasone is a potential alternative for pregnant women requiring inhaled steroids for effective asthma or allergy management. Low-dose inhaled corticosteroids are considered first line therapy for control of mild persistent asthma during pregnancy according to the guidelines of the National Asthma Education and Prevention Program NAEPP Asthma and Pregnancy Working Group.
Data on the use of medium to high dose inhaled corticosteroid during pregnancy are limited. However, dose titration may be considered for those with moderate to severe persistent asthma, preferably using budesonide.
Due to the availability of safety information during pregnancy, budesonide is preferred over other inhaled corticosteroid. However, there are no data to indicate safety concerns with other inhaled corticosteroids, and maintaining a previously established treatment regimen may be more beneficial to the patient. Selection of any pharmacologic treatment for asthma control during pregnancy should include the specific needs of the patient, based on an individual evaluation, and consideration of the potential benefits or risks to the fetus.
Corticosteroids distribute into breast-milk in low concentrations; according to FDA-approved product labels of beclomethasone, caution should be exercised when administering beclomethasone to women who are breast-feeding. Beclomethasone via inhaled administration typically results in low systemic concentrations; therefore, the amount excreted into breast-milk after inhalation is expected to be very low.
Reviewers and an expert panel consider inhaled and oral corticosteroids acceptable to use during breast-feeding. Due to greater availability of data in pregnancy, budesonide is the preferred agent in this population. However, there are no data to indicate safety concerns with other inhaled corticosteroids and maintaining a previously established treatment regimen may be more beneficial to the patient.
Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally administered drug, healthcare providers are encouraged to report the adverse effect to the FDA.
The safety and efficacy of nasally- and orally-inhaled formulations of beclomethasone in children varies depending on the product. A reduction in growth velocity in children may occur as a result of inadequate control of chronic diseases e. Growth inhibition has been observed in the absence of laboratory evidence of hypothalamic-pituitary-adrenal HPA suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients.
The long-term effects of this reduction in growth velocity, including the impact on final adult height, are unknown. In a 56 week study of asthmatic children 6 to 8 years of age receiving montelukast 5 mg per day, inhaled beclomethasone mcg twice daily, or placebo, children receiving either montelukast or placebo had higher growth rates than those receiving inhaled beclomethasone.
Health care professionals should closely follow the growth of children taking beclomethasone and weigh the benefits of therapy and disease control against the possibility of growth suppression and HPA-suppression. Pediatric patients receiving maximal dosages of beclomethasone oral or intranasal inhalation may be more susceptible to these effects.
To minimize the effects of intranasal or orally inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Systemic absorption of inhaled corticosteroids has produced reversible hyperglycemia and glucosuria in some patients.
Inhaled corticosteroids should generally be used with caution in those patients with diabetes mellitus. Exacerbation of diabetes may occur with significant systemic absorption of the inhaled corticosteroid. Rare instances of glaucoma, increased intraocular pressure, and cataracts have been reported after the inhaled administration of corticosteroids.
Use inhaled beclomethasone with caution in patients potentially predisposed to these conditions; have patients using beclomethasone report any unexplained visual disturbance promptly. To avoid adverse ophthalmic effects related to drug administration, remind patients to avoid unintended ocular exposure by actuating the medication properly.
Patients with a change in vision or a history of increased intraocular pressure, glaucoma, or cataracts should be closely monitored during corticosteroid therapy. Consider referral to an ophthalmologist in patients who develop ocular symptoms or who use beclomethasone long term. Although true corticosteroid hypersensitivity is rare, patients who have demonstrated a prior hypersensitivity reaction to beclomethasone should not receive any form of beclomethasone.
It is possible, though also rare, that such patients will display cross-hypersensitivity to other corticosteroids. It is advisable that patients who have a hypersensitivity reaction to any corticosteroid undergo skin testing, which, although not a conclusive predictor, may help to determine if hypersensitivity to another corticosteroid exists.
Such patients should be carefully monitored during and following the administration of any corticosteroid. Use beclomethasone with caution in patients with psychosis. During postmarketing experience, psychiatric events and behavioral changes such as aggression, depression, sleep disorders, psychomotor hyperactivity, and suicidal ideation have been reported; these effects were primarily reported in children.
Use inhaled and intranasal beclomethasone cautiously in patients with severe hepatic disease as the drug is primarily eliminated by the liver. Adverse effects may be more pronounced in this population. The OBRA guidelines caution that orally inhaled corticosteroids, such as beclomethasone, can cause throat irritation and oral candidiasis, particularly if the mouth is not rinsed after administration.
Abatacept: Moderate Concomitant use of immunosuppressives, as well as long-term corticosteroids, may potentially increase the risk of serious infection in abatacept treated patients. Advise patients taking abatacept to seek immediate medical advice if they develop signs and symptoms suggestive of infection.
Acetaminophen; Aspirin, ASA; Caffeine: Moderate Monitor for gastrointestinal toxicity during concurrent corticosteroid and salicylate use.
Concomitant use increases the risk of GI bleeding. In patients receiving concomitant corticosteroids and chronic use of salicylates, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance.
Acetaminophen; Aspirin: Moderate Monitor for gastrointestinal toxicity during concurrent corticosteroid and salicylate use. Acetaminophen; Aspirin; Diphenhydramine: Moderate Monitor for gastrointestinal toxicity during concurrent corticosteroid and salicylate use.
Acetaminophen; Caffeine; Magnesium Salicylate; Phenyltoloxamine: Moderate Monitor for gastrointestinal toxicity during concurrent corticosteroid and salicylate use. Acetaminophen; Caffeine; Phenyltoloxamine; Salicylamide: Moderate Monitor for gastrointestinal toxicity during concurrent corticosteroid and salicylate use. Acetaminophen; Chlorpheniramine; Dextromethorphan; Phenylephrine: Moderate The therapeutic effect of phenylephrine may be increased in patient receiving corticosteroids, such as hydrocortisone.
Monitor patients for increased pressor effect if these agents are administered concomitantly. Acetaminophen; Chlorpheniramine; Phenylephrine : Moderate The therapeutic effect of phenylephrine may be increased in patient receiving corticosteroids, such as hydrocortisone. Acetaminophen; Chlorpheniramine; Phenylephrine; Phenyltoloxamine: Moderate The therapeutic effect of phenylephrine may be increased in patient receiving corticosteroids, such as hydrocortisone.
Acetaminophen; Dextromethorphan; Guaifenesin; Phenylephrine: Moderate The therapeutic effect of phenylephrine may be increased in patient receiving corticosteroids, such as hydrocortisone. Acetaminophen; Dextromethorphan; Phenylephrine: Moderate The therapeutic effect of phenylephrine may be increased in patient receiving corticosteroids, such as hydrocortisone.
Acetaminophen; Guaifenesin; Phenylephrine: Moderate The therapeutic effect of phenylephrine may be increased in patient receiving corticosteroids, such as hydrocortisone. Acetazolamide: Moderate Corticosteroids may increase the risk of hypokalemia if used concurrently with acetazolamide.
Hypokalemia may be especially severe with prolonged use of corticotropin, ACTH. Acetohexamide: Moderate Monitor blood glucose during concomitant corticosteroid and sulfonylurea use; a sulfonylurea dose adjustment may be necessary. Corticosteroids may increase blood glucose concentrations.
Risk factors for impaired glucose tolerance due to corticosteroids include the corticosteroid dose and duration of treatment. Corticosteroids stimulate hepatic glucose production and inhibit peripheral glucose uptake into muscle and fatty tissues, producing insulin resistance. Decreased insulin production may occur in the pancreas due to a direct effect on pancreatic beta cells. Adalimumab: Moderate Closely monitor for the development of signs and symptoms of infection if coadministration of a corticosteroid with adalimumab is necessary.
Adalimumab treatment increases the risk for serious infections that may lead to hospitalization or death. Patients taking concomitant immunosuppressants including corticosteroids may be at greater risk of infection. Albiglutide: Moderate Monitor blood glucose during concomitant corticosteroid and incretin mimetic use; an incretin mimetic dose adjustment may be necessary.
Alemtuzumab: Moderate Concomitant use of alemtuzumab with immunosuppressant doses of corticosteroids may increase the risk of immunosuppression. Monitor patients carefully for signs and symptoms of infection. Aliskiren; Amlodipine; Hydrochlorothiazide, HCTZ: Moderate Monitor potassium concentrations during concomitant corticosteroid and thiazide diuretic use due to risk for additive hypokalemia; potassium supplementation may be necessary.
Both corticosteroids and thiazide diuretics cause increased renal potassium loss. Aliskiren; Hydrochlorothiazide, HCTZ: Moderate Monitor potassium concentrations during concomitant corticosteroid and thiazide diuretic use due to risk for additive hypokalemia; potassium supplementation may be necessary.
Alogliptin; Metformin: Moderate Monitor blood glucose during concomitant corticosteroid and metformin use; a metformin dose adjustment may be necessary. Alpha-glucosidase Inhibitors: Moderate Monitor patients receiving antidiabetic agents closely for worsening glycemic control when corticosteroids are instituted and for signs of hypoglycemia when corticosteroids are discontinued. Systemic and inhaled corticosteroids are known to increase blood glucose and worsen glycemic control in patients taking antidiabetic agents.
The main risk factors for impaired glucose tolerance due to corticosteroids are the dose of steroid and duration of treatment. Altretamine: Minor Concurrent use of altretamine with other agents which cause bone marrow or immune suppression such as corticosteroids may result in additive effects. Ambenonium Chloride: Moderate Concomitant use of anticholinesterase agents, such as ambenonium chloride, and corticosteroids may produce severe weakness in patients with myasthenia gravis.
If possible, anticholinesterase agents used to treat myasthenia should be withdrawn at least 24 hours before initiating corticosteroid therapy. Amifampridine: Moderate Carefully consider the need for concomitant treatment with systemic corticosteroids and amifampridine, as coadministration may increase the risk of seizures. If coadministration occurs, closely monitor patients for seizure activity. Seizures have been observed in patients without a history of seizures taking amifampridine at recommended doses.
Systemic corticosteroids may increase the risk of seizures in some patients. Amiloride; Hydrochlorothiazide, HCTZ: Moderate Monitor potassium concentrations during concomitant corticosteroid and thiazide diuretic use due to risk for additive hypokalemia; potassium supplementation may be necessary. Aminolevulinic Acid: Minor Corticosteroids administered prior to or concomitantly with photosensitizing agents used in photodynamic therapy may decrease the efficacy of the treatment.
Aminosalicylate sodium, Aminosalicylic acid: Moderate Monitor for gastrointestinal toxicity during concurrent corticosteroid and salicylate use. Amlodipine; Valsartan; Hydrochlorothiazide, HCTZ: Moderate Monitor potassium concentrations during concomitant corticosteroid and thiazide diuretic use due to risk for additive hypokalemia; potassium supplementation may be necessary.
Amphotericin B cholesteryl sulfate complex ABCD : Moderate The potassium-wasting effects of corticosteroid therapy can be exacerbated by concomitant administration of other potassium-depleting drugs including amphotericin B. Serum potassium levels should be monitored in patients receiving these drugs concomitantly. Amphotericin B lipid complex ABLC : Moderate The potassium-wasting effects of corticosteroid therapy can be exacerbated by concomitant administration of other potassium-depleting drugs including amphotericin B.
Amphotericin B liposomal LAmB : Moderate The potassium-wasting effects of corticosteroid therapy can be exacerbated by concomitant administration of other potassium-depleting drugs including amphotericin B. Amphotericin B: Moderate The potassium-wasting effects of corticosteroid therapy can be exacerbated by concomitant administration of other potassium-depleting drugs including amphotericin B.
Arsenic Trioxide: Moderate Caution is advisable during concurrent use of arsenic trioxide and corticosteroids as electrolyte imbalance caused by corticosteroids may increase the risk of QT prolongation with arsenic trioxide.
Articaine; Epinephrine: Moderate Monitor potassium concentrations during concomitant corticosteroid and epinephrine use due to risk for additive hypokalemia; potassium supplementation may be necessary. Corticosteroids may potentiate the hypokalemic effects of epinephrine. Asparaginase Erwinia chrysanthemi: Moderate Concomitant use of L-asparaginase with corticosteroids can result in additive hyperglycemia.
L-Asparaginase transiently inhibits insulin production contributing to hyperglycemia seen during concurrent corticosteroid therapy. Insulin therapy may be required in some cases. Administration of L-asparaginase after rather than before corticosteroids reportedly has produced fewer hypersensitivity reactions. Aspirin, ASA: Moderate Monitor for gastrointestinal toxicity during concurrent corticosteroid and salicylate use. Aspirin, ASA; Butalbital; Caffeine: Moderate Monitor for gastrointestinal toxicity during concurrent corticosteroid and salicylate use.
Aspirin, ASA; Caffeine: Moderate Monitor for gastrointestinal toxicity during concurrent corticosteroid and salicylate use. Aspirin, ASA; Caffeine; Dihydrocodeine: Moderate Monitor for gastrointestinal toxicity during concurrent corticosteroid and salicylate use.
Aspirin, ASA; Caffeine; Orphenadrine: Moderate Monitor for gastrointestinal toxicity during concurrent corticosteroid and salicylate use.
Aspirin, ASA; Carisoprodol: Moderate Monitor for gastrointestinal toxicity during concurrent corticosteroid and salicylate use. Aspirin, ASA; Carisoprodol; Codeine: Moderate Monitor for gastrointestinal toxicity during concurrent corticosteroid and salicylate use.
Aspirin, ASA; Dipyridamole: Moderate Monitor for gastrointestinal toxicity during concurrent corticosteroid and salicylate use. Aspirin, ASA; Omeprazole: Moderate Monitor for gastrointestinal toxicity during concurrent corticosteroid and salicylate use. Aspirin, ASA; Oxycodone: Moderate Monitor for gastrointestinal toxicity during concurrent corticosteroid and salicylate use.
Aspirin, ASA; Pravastatin: Moderate Monitor for gastrointestinal toxicity during concurrent corticosteroid and salicylate use. Atenolol; Chlorthalidone: Moderate Monitor potassium concentrations during concomitant corticosteroid and thiazide diuretic use due to risk for additive hypokalemia; potassium supplementation may be necessary. Atracurium: Moderate Limit the period of use of neuromuscular blockers and corticosteroids and only use when the specific advantages of the drugs outweigh the risks for acute myopathy.
An acute myopathy has been observed with the use of high doses of corticosteroids in patients receiving concomitant long-term therapy with neuromuscular blockers. Clinical improvement or recovery after stopping therapy may require weeks to years.
Send the page " " to a friend, relative, colleague or yourself. We do not record any personal information entered above. Synthetic halogenated glucocorticoid Used via oral inhalation for maintenance treatment of asthma or COPD Used intranasally for allergic or nonallergic vasomotor rhinitis, or prevention of nasal polyps following sinus surgery. For patients switching from another ICS, select the initial dose based on previous product use and disease severity 40 to mcg twice daily.
May titrate after 2 weeks of initial therapy if response is not adequate. Improvement in asthma symptoms can occur within 24 hours of the beginning of treatment and should be expected within the first or second week, but maximum benefit should not be expected until 3 to 4 weeks of therapy. Improvement in pulmonary function is usually apparent within 1 to 4 weeks after the start of therapy.
Titrate to the lowest effective dose once asthma stability is achieved. For patients switching from another ICS, select the starting dosage based on the previous product use and disease severity 40 to mcg twice daily. Base starting dosage on previous asthma therapy and asthma severity. If no improvement is seen after 3 weeks of continuous administration, discontinue use. Patients not responding or those with more severe symptoms may use 2 sprays into each nostril twice a day.
Once symptoms are controlled, the dose should be decreased to 1 spray into each nostril twice a day. Patients not responding or those with more severe symptoms may use 2 sprays into each nostril twice per day. Once symptoms are controlled, the dose should be decreased to 1 spray into each nostril twice per day. For other patients, select dose based on previous therapy and asthma severity 40 to mcg twice daily. Titrate to the lowest effective dose.
Efficacy for EIB has been studied in pediatric patients. Efficacy for EIB has been studied in pediatric patients, using as low as once-daily dosing. Typical doses range from 40 to mcg inhaled orally twice daily, using commercially available products. High dose therapy up to 1, mcg inhaled twice daily has also been studied, using formulations not commercially available. Do not use for the relief of acute bronchospasm; use a short-acting beta-2 agonist SABA. An ICS combined with a LABA is more effective than the individual components in improving lung function and health status and reducing exacerbations in patients with exacerbations and moderate to very severe COPD; however clinical trials failed to demonstrate a statistically significant effect on survival.
At follow-up, if the patient is still experiencing dyspnea, consider switching inhaler device and investigate for other causes of dyspnea. Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that no dosage adjustments are needed. Specific guidelines for dosage adjustments in renal impairment are not available; it appears that no dosage adjustments are needed.
General Information To avoid the spread of infection, do not use the inhaler for more than one person. Instruct patient on proper use of the inhaler device; see manufacturer's "Instructions for Use". Oral inhalation HFA pressurized, metered-dose aerosol Qvar Redihaler : The canister does not require shaking prior to administration; do not shake the inhaler with the cap open to avoid possible actuation of the device.
The white cap on the Redihaler must be closed before each inhalation; do not open the white cap until ready to give the inhalation. If the dose requires more than 1 inhalation the white cap must be closed between each inhalation.
Do not use with a spacer device or volume holding chamber with the Redihaler. The Redihaler does not require priming. The Redihaler has a dose counter attached to the actuator. When first opened, the number will be displayed. The dose counter will count down each time a spray is released. When the dose counter reaches 20, red numbers appear warning to refill the medication. Instruct patient on proper inhalation technique for the device. After administration, have patient rinse mouth thoroughly with water without swallowing to remove beclomethasone deposited in the mouth.
Keep the inhaler clean and dry. For normal hygiene, clean the mouthpiece of the inhaler with a clean dry tissue or cloth. Do not put any part of the Redihaler in water; if washed or placed in water the inhaler must be replaced. Never take the Redihaler apart. Throw away the Redihaler when the dose counter displays 0 background will be a solid red or the product expires, whichever comes first.
Do not throw away in a fire or incinerator. Storage: Keep the white cap on the inhaler closed during storage. Store so the inhaler rests on the concave end of the canister with the plastic actuator on top when not being used.
Store at room temperature. Do not use or store near heat or open flame. Exposure to temperatures above degrees F 49 degrees C may cause the canister to burst. Different nasal dosage forms are commercially available. Products are not always interchangeable due to differences in route of administration and in the amount of active drug released per spray. To avoid the spread of infection, do not use the container for more than 1 person. Nasal inhalation metered-dose aerosol i.
Prior to first use, instruct the patient to prime the pump by actuating 4 times into the air, away from the eyes and face. After the initial priming, the dose-counter should read actuation products or 60 actuation products. If the canister is not used for 7 consecutive days, instruct the patient to prime by actuating 2 times.
Instruct patient on proper administration technique see manufacturer-provided patient instructions. After administration, wipe the nasal actuator tip with a clean, dry tissue or cloth. Replace the cap right after cleaning. Nasal inhalation pump spray e. Prior to first use, instruct the patient to prime the pump by actuating 6 times into the air or until a fine spray appears, away from the eyes and face. If the pump is not used for 7 consecutive days, instruct the patient to prime by actuating until a fine spray appears.
After administration, rinse the tip of the bottle with hot water, taking care not to suck water into the bottle, and dry with a clean tissue. Beconase AQ: - Store at room temperature between 59 to 86 degrees F Qnasl: - Exposure to temperatures above degrees F may cause bursting - Keep away from heat and flame - Protect from freezing - Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F - Store upright Qnasl Children's: - Exposure to temperatures above degrees F may cause bursting - Keep away from heat and flame - Protect from freezing - Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F - Store upright QVAR: - Exposure to temperatures above degrees F may cause bursting - Flammable, keep away from heat and flame - Store at 77 degrees F; excursions permitted to degrees F QVAR RediHaler: - Exposure to temperatures above degrees F may cause bursting - Flammable, keep away from heat and flame - Store at 77 degrees F; excursions permitted to degrees F.
Use of beclomethasone does not contraindicate administration of live-virus vaccines. According to the Advisory Committee on Immunization Practices ACIPadministration of live-virus vaccines is safe and effective when steroid therapy is administered by the inhalation route. Inhaled beclomethasone is contraindicated as primary therapy for patients with status asthmaticus or other types of acute episodes of asthma, such as acute bronchospasm, for which intensive and immediate therapy is warranted.
Patients should be advised that beclomethasone is not to be used as a bronchodilator and is not indicated for relief of acute bronchospasm. Although inhaled corticosteroids ICSs are not indicated for primary treatment of an acute exacerbation, they may be initiated at any time during an exacerbation for patients not using long-term control therapy.
An ICS may also be continued during an exacerbation for patients previously using the drug for chronic control. Additionally, the drug is contraindicated for use in any patient with a known hypersensitivity to beclomethasone. As with other inhaled asthma medications, paradoxical bronchospasm can occur with an immediate increase in wheezing after administration of inhaled beclomethasone that may be life-threatening.
If bronchospasm occurs after dosing, treat the patient immediately with a fast-acting inhaled bronchodilator, discontinue beclomethasone, and institute alternative therapy. Systemic absorption of inhaled or intranasal beclomethasone may result in varying complications depending on the clinical situation and type of administration. Carefully observe patients for evidence of systemic corticosteroid effects and adrenal insufficiency, particularly during periods of physiologic stress e.
Systemic absorption of inhaled or intranasal corticosteroids has produced reversible hypothalamic-pituitary-adrenal HPA suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients; use with caution in patient's with underlying Cushing's syndrome.
To minimize the risk of HPA dysfunction, do not exceed recommended dosages and titrate patients to the lowest effective dosage. Patients with low body mass index BMI may have an increased risk of HPA suppression; some experts recommend adrenal screening in this population. If signs of HPA suppression occur, the drug should be slowly reduced; intranasal corticosteroids should be ultimately discontinued.
If HPA suppression occurs with any beclomethasone formulation, patients will require systemic corticosteroids during periods of physiologic stress. If surgery is required, patients should notify all health care providers that they have received corticosteroids within the last 12 months. Use beclomethasone with caution when substituting it for systemic corticosteroid administration and avoid abrupt discontinuation; deaths due to adrenal insufficiency have been reported in asthma patients during and after such a change.
Beclomethasone may not produce systemic concentrations high enough to avoid adrenocortical insufficiency in patients transitioning from systemic corticosteroids. Adult patients who have been maintained on at least 20 mg of prednisone equivalent may be most susceptible; the precise dosage that increases risk in children is not as clearly defined.
Recommended doses of inhaled corticosteroids ICSs provide less than normal physiologic amounts of systemic glucocorticoid and do not provide the mineralocorticoid necessary for coping with stress. Patients receiving ICS may require initiation or resumption of systemic corticosteroids during periods of stress or during severe asthma attacks.
When transferring patients to ICS therapy, systemic corticosteroids should be weaned slowly. Monitor patients closely for asthma control e. Infrequently, signs and symptoms of corticosteroid withdrawal may occur, requiring supplemental systemic corticosteroids. The incidence or course of acute viral infection or bacterial infection is probably minimally affected by inhaled corticosteroids in most immunocompetent individuals. However, the use of inhaled beclomethasone in the presence of infection, specifically active or latent tuberculosis of the respiratory tract; untreated systemic fungal, bacterial, parasitic, or viral infections; or ocular herpes infection should be initiated or continued cautiously, if at all.
Because of the potential for worsening infection, beclomethasone therapy may need to be interrupted during some active infections. Chickenpox varicella and measles can have a more serious or even fatal course in susceptible children using corticosteroids; the exact risk associated with inhaled beclomethasone is unclear.
If an unimmunized patient is exposed to chickenpox or measles, proper prophylaxis may be indicated. Corticosteroid therapy can reactivate tuberculosis and should not be used except when chemoprophylaxis is instituted concomitantly. The use of nasal or orally inhaled beclomethasone may result in localized fungal infection of the nose, mouth, and pharynx with Candida albicans. Instruct patients to rinse mouth after each use of orally inhaled beclomethasone to minimize risk.
If oropharyngeal candidiasis develops, it should be treated with appropriate local or systemic antifungal therapy while still continuing beclomethasone therapy; temporary interruption of inhaler use should only be done under close medical supervision.
Initial dose: 40 mcg via oral inhalation twice a day; Maintenance dose: After 2 weeks, may increase dose to 80 mcg twice daily for additional. No prior history of inhaled corticosteroid use: mcg inhaled orally every 12 hours initially; may increase the dose if needed. Adult: As aerosol or dry powd inhaler: Initially, mcg daily for mild cases; mcg daily for moderate cases; mcg daily for severe cases. mcg (1 to 2 oral inhalations of 40 mcg/actuation) twice daily, approximately 12 hours apart is the recommended dosing for asthma maintenance in. The usual starting dose is micrograms twice a day. In more severe cases the starting dose may need to increase to to micrograms per day which may. Selection of any pharmacologic treatment for asthma control during pregnancy should include the specific needs of the patient, based on an individual evaluation, and consideration of the potential benefits or risks to the fetus. Oral Inhalation dosage inhalation aerosol; i. At follow-up, if the patient is still experiencing dyspnea, consider switching inhaler device and investigate for other causes of dyspnea. Rinsing your mouth with water after each dose may help prevent hoarseness, throat irritation, and infection in the mouth.Back to Medicines A to Z. Beclometasone inhalers sometimes called "puffers" are used for asthma and chronic obstructive pulmonary disease COPD. They are known as "preventer" inhalers and are often brown or beige. If you have asthma or COPD, they help stop you getting symptoms.
Beclometasone inhalers are available on prescription only. Some inhalers contain beclometasone mixed with other medicines that help your breathing.
Beclometasone sometimes written as "beclomethasone" is a type of medicine known as a corticosteroid or steroid. Children aged 5 years and older can use beclometasone inhalers for asthma. Beclometasone is not suitable for some people. To make sure it's safe for you, tell your doctor if you:.
It's important to use your beclometasone inhaler regularly to manage your condition. Keep using it, even if you do not have any symptoms. After using your inhaler, always put the lid back on to keep it clean. Always follow the instructions from your doctor, or your asthma or respiratory nurse. They may tell you to use your inhaler more often, up to 4 times a day, or to have more than 2 puffs at a time. This depends on how bad your breathing is and which inhaler you're using.
There are different types of beclometasone inhaler. It's very important to use your inhaler properly. This is so you get the right amount of beclometasone into your lungs and the most benefit from your medicine. Before using your inhaler, read the information leaflet that came with it. This leaflet contains instructions and diagrams to show you how to use the inhaler, how to keep it clean, and how long to use it before getting a replacement.
Asthma UK has some short videos showing you how to use your inhaler to help you manage your symptoms. You can search by type of inhaler and by brand such as Clenil, Fostair or Qvar. If you use a pressurised metered-dose inhaler for example, you can watch a pMDI video. To get the most from your inhaler, it's important to have your technique checked regularly. If you're not sure how to use your inhaler, or your technique has not been checked for a year, ask your doctor, nurse or a pharmacist to watch you use it.
If you or your child find it difficult to use an inhaler, your doctor or nurse may give you a spacer to use with it. Spacers can reduce the risk of side effects affecting your mouth and throat. They are particularly useful for giving beclometasone to young children. A spacer is a large plastic container with a mouthpiece and a hole for the inhaler.
It makes it easier to get the right amount of beclometasone into your lungs. Your doctor, nurse or a pharmacist can show you how to use a spacer with your inhaler. Your dose may go up or down depending on how bad your breathing is. You will be prescribed the lowest dose that controls your symptoms.
If you have agreed a personal action plan with your doctor or nurse, follow your action plan. Use your inhaler as soon as you remember. If you forget doses often, it may help to set an alarm to remind you. You could also ask your pharmacist for advice on other ways to help you remember to take your medicine. Do not stop using beclometasone suddenly, even if you feel better, without speaking to your doctor or nurse first.
If you are using a steroid inhaler regularly, ask your doctor, nurse or a pharmacist if you need to carry a blue steroid card. If you need any medical or dental treatment, show your blue steroid card to the doctor, dentist or pharmacist so they know that you're taking beclometasone. Like all medicines, beclometasone can cause side effects although not everyone gets them.
With inhaled beclometasone very little medicine gets into the rest of your body, so it's unlikely to give you side effects. Ask your doctor if you need to carry a steroid emergency card.
Keep taking the medicine but talk to your doctor if these side effects bother you or do not go away:. It's unusual to have any serious side effects when using a beclometasone inhaler.
Side effects are more likely if you're on a higher dose of beclometasone for a long time more than a few months. It happens rarely but it is possible to have a serious allergic reaction anaphylaxis to beclometasone. This is different to an asthma attack. If you or your child have asthma symptoms, such as wheezing or have tightness in the chest or throat, use a reliever inhaler.
You could be having a serious allergic reaction and may need immediate treatment in hospital. Taking beclometasone at higher doses for a long time can slow down the normal growth of children and teenagers. Your child's doctor will monitor their height and weight carefully for as long as they're taking this medicine. This will help them spot any slowing down of your child's growth and change their treatment if needed.
Even if your child's growth slows down, it does not seem to have much effect on their overall adult height. Talk to your doctor if you're worried.
They will be able to explain the benefits and risks of giving your child beclometasone. You can report any suspected side effect to the UK safety scheme. These are not all the side effects of beclometasone.
For a full list see the leaflet inside your medicines packet. Beclometasone inhalers are safe to use during pregnancy. Since it is taken into the lungs, very little of the medicine gets into your bloodstream and almost none gets to your baby. Even if a small amount does get to your baby, it will not harm them. It's important to keep using beclometasone in pregnancy to ensure that your asthma or COPD is well controlled.
Having a lung condition and breathing difficulties is dangerous for you and your baby. You may find that you need extra beclometasone during pregnancy. This is fine and it's safe to increase the dose if you need to. If your asthma or COPD gets worse during pregnancy then contact your doctor, midwife or specialist.
For more information about how using a beclometasone inhaler might affect you and your baby during pregnancy, read this leaflet on inhaled corticosteroids on the Best Use of Medicines in Pregnancy BUMPS website. It's OK to use your beclometasone inhaler as normal while you're breastfeeding. When beclometasone is used as an inhaler, tiny amounts are likely to be in breast milk.
It is very unlikely to cause any side effects in your baby. If you notice that your baby is not feeding as well as usual, or if you have any other concerns about your baby, talk to your health visitor, midwife or doctor as soon as possible. Some medicines and beclometasone interfere with each other. This can increase your chance of side effects, or it may mean changing your beclometasone dose.
There's very little information about taking herbal remedies and supplements while taking or using beclometasone. Ask a pharmacist for advice. Tell your doctor or pharmacist if you're taking any other medicines, including herbal remedies, vitamins or supplements. Steroids closely copy the effects of natural hormones produced in your adrenal glands.
The adrenal glands are next to your kidneys. Beclometasone inhalers are called preventers. They work by calming down your immune system. This reduces the swelling in your lungs that makes it difficult to breathe. It also prevents you getting symptoms such as wheezing and coughing.
Beclometasone on its own does not help treat an asthma attack when you suddenly get coughing, wheezing and breathlessness. A Fostair inhaler may be used as both a preventer and a reliever to relieve any symptoms when you get them. You'll usually start to wheeze less after using beclometasone for 3 to 7 days. Once your symptoms have improved, you may find you need to use your other inhaler called a "reliever" less often.
If your shortness of breath or wheezing does not get better after 7 days of using beclometasone, or if it gets worse, let your doctor or nurse know as soon as possible. You'll usually use your beclometasone inhaler for a long time. It helps prevent your asthma or COPD getting worse. If you use your inhaler as recommended by your doctor, nurse or pharmacist you're unlikely to get any lasting side effects. Inhalers generally deliver a small amount of steroid medicine exactly where you need it.
This limits the amount of steroid reaching the rest of your body. It also keeps the risk of side effects as low as possible. However, for children and teenagers using a high dose steroid inhaler, their height and weight need to be monitored carefully. This is to make sure the steroid is not affecting their growth. Talk to their doctor if you're worried. Adults taking high doses either using an inhaler, or as tablets to help control more severe symptoms have an increased risk of getting adrenal gland problems or weak bones osteoporosis over time.
Comments
Post a Comment